Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 311

Related Citations for PubMed (Select 22429766)

1.

Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL; Urologic Diseases in America Project.

BJU Int. 2012 Oct;110(7):1050-9. doi: 10.1111/j.1464-410X.2011.10867.x. Epub 2012 Mar 19.

2.

Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: Results from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Breyer BN, Huang WY, Rabkin CS, Alderete JF, Pakpahan R, Beason TS, Kenfield SA, Mabie J, Ragard L, Wolin KY, Grubb Iii RL, Andriole GL, Sutcliffe S.

BJU Int. 2015 Jan 20. doi: 10.1111/bju.13050. [Epub ahead of print]

PMID:
25601300
3.

The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.

Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC.

J Sex Med. 2008 Jul;5(7):1702-7. doi: 10.1111/j.1743-6109.2007.00713.x.

PMID:
18194186
4.

Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.

Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.

BJU Int. 2012 Dec;110(11 Pt C):E837-44. doi: 10.1111/j.1464-410X.2012.11288.x. Epub 2012 Jun 19.

PMID:
22712582
5.

Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.

Fukuta F, Masumori N, Mori M, Tsukamoto T.

BJU Int. 2012 Oct;110(7):1023-9. doi: 10.1111/j.1464-410X.2011.10866.x. Epub 2012 Jan 11.

PMID:
22233355
6.

[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].

Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi AR, Faix A, Desgrandchamps F, de la Taille A; Comité des troubles mictionnels de l’homme de l’association française d’urologie.

Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. French.

PMID:
23178093
7.

Prevalence of BPH and lower urinary tract symptoms in West Africans.

Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, Tettey Y, Adjei A, Jadallah S, Li Y, Chu LW, Chia D, Niwa S, Partin A, Thompson IM, Roehrborn C, Hoover RN, Hsing AW.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):170-6. doi: 10.1038/pcan.2011.43. Epub 2011 Sep 13.

PMID:
21912428
8.

Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.

Carballido J, Fourcade R, Pagliarulo A, Brenes F, Boye A, Sessa A, Gilson M, Castro R.

Int J Clin Pract. 2011 Sep;65(9):989-96. doi: 10.1111/j.1742-1241.2011.02735.x. Epub 2011 Jul 7.

PMID:
21733048
9.
10.

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Roehrborn CG, Boyle P, Gould AL, Waldstreicher J.

Urology. 1999 Mar;53(3):581-9.

PMID:
10096388
11.

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR.

Am J Epidemiol. 2012 Jul 15;176(2):156-63. doi: 10.1093/aje/kwr524. Epub 2012 Jun 28.

12.

A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.

Oudot A, Oger S, Behr-Roussel D, Caisey S, Bernabé J, Alexandre L, Giuliano F.

BJU Int. 2012 Nov;110(9):1352-8. doi: 10.1111/j.1464-410X.2012.11085.x. Epub 2012 Mar 27.

PMID:
22448674
13.

Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study.

Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW.

Br J Cancer. 2012 Jun 26;107(1):207-14. doi: 10.1038/bjc.2012.227. Epub 2012 Jun 21.

14.

The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.

Frånlund M, Carlsson S, Stranne J, Aus G, Hugosson J.

BJU Int. 2012 Sep;110(5):638-43. doi: 10.1111/j.1464-410X.2012.10962.x. Epub 2012 Apr 30.

PMID:
22540895
15.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

16.
17.

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.

MacDonald R, Tacklind JW, Rutks I, Wilt TJ.

BJU Int. 2012 Jun;109(12):1756-61. doi: 10.1111/j.1464-410X.2012.11172.x. Epub 2012 May 2. Review.

18.

Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.

Chung BH, Hong SJ, Cho JS, Seong DH.

BJU Int. 2006 Apr;97(4):742-6. Erratum in: BJU Int. 2006 May;97(5):1135.

PMID:
16536765
19.

Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.

Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE, Jacobsen SJ.

Diabetes Care. 2008 Mar;31(3):476-82. Epub 2007 Dec 10.

PMID:
18071006
20.

Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.

Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang J.

Int J Clin Pract. 2007 Sep;61(9):1437-45.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk